Decreased expression of peroxisome proliferator activated receptor γ in CFTR-/- mice

Journal of Cellular Physiology

Volumn 200, Issue 2, 2004, Pages 235-244

  Ollero, Mario ^a   Junaidi, Omer ^a   Zaman, Munir M ^a   Tzameli, Iphigenia ^a   Ferrando, Adolfo A ^a   Andersson, Charlotte ^a   Blanco, Paola G ^a   Bialecki, Eldad ^a   Freedman, Steven D ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LIGAND; MESSENGER RNA; OLIGONUCLEOTIDE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; RNA; ROSIGLITAZONE; TRANSMEMBRANE CONDUCTANCE REGULATOR;

ADIPOSE TISSUE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COLON MUCOSA; CONTROLLED STUDY; CYSTIC FIBROSIS; DNA RESPONSIVE ELEMENT; EPITHELIUM CELL; ILEUM MUCOSA; IMMUNOHISTOCHEMISTRY; KNOCKOUT MOUSE; LIVER; LUNG; METABOLIC DISORDER; MOUSE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN DNA BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ANIMALS; BLOTTING, WESTERN; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; DOWN-REGULATION; FIBRINOLYTIC AGENTS; GENE EXPRESSION REGULATION; IMMUNOHISTOCHEMISTRY; INTESTINAL MUCOSA; MICE; MICE, KNOCKOUT; RECEPTORS, CYTOPLASMIC AND NUCLEAR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; THIAZOLIDINEDIONES; TRANSCRIPTION FACTORS;

EID: 3042856185     PISSN: 00219541     EISSN: None     Source Type: Journal    
DOI: 10.1002/jcp.20020     Document Type: Article

References (54)

1. Altiok S, Xu M, Spiegelman BM. 1997. PPARgamma induces cell cycle withdrawal: Inhibition of E2F/DP DNA-binding activity via down-regulation of PP2A. Genes Dev 11(15):1987-1998.
2. Barrett MT, Glogovac J, Porter P, Reid BJ, Rabinovitch PS. 1999. High yields of RNA and DNA suitable for array analysis from cell sorter purified epithelial cell and tissue populations. Nat Genet 23(poster abstracts):32-33.
3. Berger J, Moller DE. 2002. The mechanisms of action of PPARs. Annu Rev Med 53:409-435.
4. Boyer JL. 1996. Bile duct epithelium: Frontiers in transport physiology. Am J Physiol 270(1 Pt 1):G1-G5.
5. Brown RK, Kelly FJ. 1994. Evidence for increased oxidative damage in patients with cystic fibrosis. Pediatr Res 36(4):487-493.
6. Brown KK, Henke BR, Blanchard SG, Cobb JE, Mook R, Kaldor I, Kliewer SA, Lehmann JM, Lenhard JM, Harrington WW, Novak PJ, Faison W, Binz JG, Hashim MA, Oliver WO, Brown HR, Parks DJ, Plunket KD, Tong WQ, Menius JA, Adkison K, Noble SA, Willson TM. 1999. A novel N-aryl tyrosine activator of peroxisome proliferator-activated receptor-gamma reverses the diabetic phenotype of the Zucker diabetic fatty rat. Diabetes 48(7):1415-1424.
7. Clark RB, Bishop-Bailey D, Estrada-Hernandez T, Hla T, Puddington L, Padula SJ. 2000. The nuclear receptor PPAR gamma and immunoregulation: PPAR gamma mediates inhibition of helper T cell responses. J Immunol 164(3):1364-1371.
8. Davies GF, Khandelwal RL, Roesler WJ. 1999. Troglitazone induces expression of PPARgamma in liver. Mol Cell Biol Res Commun 2(3):202-208.
9. Davies GF, McFie PJ, Khandelwal RL, Roesler WJ. 2002. Unique ability of troglitazone to up-regulate peroxisome proliferator-activated receptor-gamma expression in hepatocytes. J Pharmacol Exp Ther 300(1):72-77.
10. Demetri GD, Fletcher CD, Mueller E, Sarraf P, Naujoks R, Campbell N, Spiegelman BM, Singer S. 1999. Induction of solid tumor differentiation by the peroxisome proliferator-activated receptor-gamma ligand troglitazone in patients with liposarcoma. Proc Natl Acad Sci USA 96(7):3951-3956.
11. Devos R, Richards JG, Campfield LA, Tartaglia LA, Guisez Y, van der Heyden J, Travernier J, Plaetinck G, Burn P. 1996. OB protein binds specifically to the choroid plexus of mice and rats. Proc Natl Acad Sci USA 93(11):5668-5673.
12. Dreyer C, Krey G, Keller H, Givel F, Helftenbein G, Wahli W. 1992. Control of the peroxisomal beta-oxidation pathway by a novel family of nuclear hormone receptors. Cell 68(5):879-887.
13. Dubuquoy L, Dharancy S, Nutten S, Pettersson S, Auwerx J, Desreumaux P. 2002. Role of peroxisome proliferator-activated receptor gamma and retinoid X receptor heterodimer in hepatogastroenterological diseases. Lancet 360(9343):1410-1418.
14. Elstner E, Muller C, Koshizuka K, Williamson EA, Park D, Asou H, Shintaku P, Said JW, Heber D, Koeffier HP. 1998. Ligands for peroxisome proliferator-activated receptorgamma and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice. Proc Natl Acad Sci USA 95(15):8806-8811.
15. Fajas L, Auboeuf D, Raspe E, Schoonjans K, Lefebvre AM, Saladin R, Najib J, Laville M, Fruchart JC, Deeb S, Vidal-Puig A, Flier J, Briggs MR, Staels B, Vidal H, Auwerx J. 1997. The organization, promoter analysis, and expression of the human PPARgamma gene. J Biol Chem 272(30):18779-18789.
16. Farrell PM, Mischler EH, Engle MJ, Brown DJ, Lau SM. 1985. Fatty acid abnormalities in cystic fibrosis. Pediatr Res 19(1):104-109.
17. Finkelstein SM, Wielinski CL, Elliott GR, Warwick WJ, Barbosa J, Wu SC, Klein DJ. 1988. Diabetes mellitus associated with cystic fibrosis. J Pediatr 112(3):373-377.
18. Freedman SD, Katz MH, Parker EM, Laposata M, Urman MY, Alvarez JG. 1999. A membrane lipid imbalance plays a role in the phenotypic expression of cystic fibrosis in cftr(-/-) mice. Proc Natl Acad Sci USA 96(24):13995-14000.
19. Hardin DS, LeBlanc A, Lukenbough S, Seilheimer DK. 1997. Insulin resistance is associated with decreased clinical status in cystic fibrosis. J Pediatr 130(6):948-956.
20. Hofmann C, Lorenz K, Braithwaite SS, Colca JR, Palazuk BJ, Hotamisligil GS, Spiegelman BM. 1994. Altered gene expression for tumor necrosis factor-alpha and its receptors during drug and dietary modulation of insulin resistance. Endocrinology 134(1):264-270.
21. Hsi LC, Wilson L, Nixon J, Eling TE. 2001. 15-lipoxygenase-1 metabolites down-regulate peroxisome proliferator-activated receptor gamma via the MAPK signaling pathway. J Biol Chem 276(37): 34545-34552.
22. Hu E, Kim JB, Sarraf P, Spiegelman BM. 1996. Inhibition of adipogenesis through MAP kinase-mediated phosphorylation of PPAR-gamma. Science 274(5295):2100-2103.
23. Iannucci A, Mukai K, Johnson D, Burke B. 1984. Endocrine pancreas in cystic fibrosis: An immunohistochemical study. Hum Pathol 15(3):278-284.
24. Issemann I, Green S. 1990. Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature 347(6294):645-650.
25. Jiang C, Ting AT, Seed B. 1998. PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. Nature 391(6662): 82-86.
26. Kallen CB, Lazar MA. 1996. Antidiabetic thiazolidinediones inhibit leptin (ob) gene expression in 3T3-L1 adipocytes. Proc Natl Acad Sci USA 93(12):5793-5796.
27. Kodera Y, Takeyama KI, Muruyama A, Suzawa M, Masuhiro Y, Kato S. 2000. Ligand type-specific interactions of peroxisome proliferator-activated receptor g with transcriptional coactivators. J Biol Chem 275(43):33201-33204.
28. Lambe KG, Tugwood JD. 1996. A human peroxisome-proliferator-activated receptor-gamma is activated by inducers of adipogenesis, including thiazolidinedione drugs. Eur J Biochem 239(1):1-7.
29. Lanng S. 2001. Glucose intolerance in cystic fibrosis patients. Paediatr Respir Rev 2(3):253-259.
30. Martin G, Schoonjans K, Lefebvre AM, Staels B, Auwerx J. 1997. Coordinate regulation of the expression of the fatty acid transport protein and acyl-CoA synthetase genes by PPARalpha and PPAR-gamma activators. J Biol Chem 272(45):28210-28217.
31. Michael LF, Lazar MA, Mendelson CR. 1997. Peroxisome proliferator- activated receptor gammal expression is induced during cyclic adenosine monophosphate-stimulated differentiation of alveolar type II pneumonocytes. Endocrinology 138(9):3695-3703.
32. Mudaliar S, Henry RR. 2001. New oral therapies for type 2 diabetes mellitus: The glitazones or insulin sensitizers. Annu Rev Med 52:239-257.
33. Mueller E, Sarraf P, Tontonoz P, Evans RM, Martin KJ, Zhang M, Fletcher C, Singer S, Spiegelman BM. 1998. Terminal differentiation of human breast cancer through PPAR gamma. Mol Cell 1(3): 465-470.
34. Nagy L, Tontonoz P, Alvarez JG, Chen H, Evans RM. 1998. Oxidized LDL regulates macrophage gene expression through ligand activation of PPARgamma. Cell 93(2):229-240.
35. Park KS, Ciaraldi TP, Lindgren K, Abrams-Carter L, Mudaliar S, Nikoulina SE, Tufari SR, Veerkamp JH, Vidal-Puig A, Henry RR. 1998. Troglitazone effects on gene expression in human skeletal muscle of type II diabetes involve up-regulation of peroxisome proliferator-activated receptor-gamma. J Clin Endocrinol Metab 83(8):2830-2835.
36. Pawliczak R, Han C, Huang XL, Demetris AJ, Shelhamer JH, Wu T. 2002. 85-kDa cytosolic phospholipase A2 mediates peroxisome proliferator-activated receptor gamma activation in human lung epithelial cells. J Biol Chem 277(36):33153-33163.
37. Ribon V, Johnson JH, Camp HS, Saltiel AR. 1998. Thiazolidinediones and insulin resistance: Peroxisome proliferator activated receptor gamma activation stimulates expression of the CAP gene. Proc Natl Acad Sci USA 95(25):14751-14756.
38. Ricote M, Li AC, Willson TM, Kelly CJ, Glass CK. 1998. The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature 391(6662):79-82.
39. Roulet M, Frascarolo P, Rappaz I, Pilet M. 1997. Essential fatty acid deficiency in well nourished young cystic fibrosis patients. Eur J Pediatr 156(12):952-956.
40. Schoonjans K, Watanabe M, Suzuki H, Mahfoudi A, Krey G, Wahli W, Grimaldi P, Staels B, Yamamoto T, Auwerx J. 1995. Induction of the acyl-coenzyme A synthetase gene by fibrates and fatty acids is mediated by a peroxisome proliferator response element in the C promoter. J Biol Chem 270(33):19269-19276.
41. Schoonjans K, Staels B, Auwerx J. 1996. The peroxisome proliferator activated receptors (PPARS) and their effects on lipid metabolism and adipocyte differentiation. Biochim Biophys Acta 1302(2):93-109.
42. Sfeir Z, Ibrahimi A, Amri E, Grimaldi P, Abumrad N. 1997. Regulation of FAT/CD36 gene expression: Further evidence in support of a role of the protein in fatty acid binding/transport. Prostaglandins Leukot Essent Fatty Acids 57(1):17-21.
43. Shibuya A, Wada K, Nakajima A, Saeki M, Katayama K, Mayumi T, Kadowaki T, Niwa H, Kamisaki Y. 2002. Nitration of PPARgamma inhibits ligand-dependent translocation into the nucleus in a macrophage-like cell line, RAW 264. FEBS Lett 525(1-3):43-47.
44. Smith U, Gogg S, Johansson A, Olausson T, Rotter V, Svalstedt B. 2001. Thiazolidinediones (PPARgamma agonists) but not PPAR-alpha agonists increase IRS-2 gene expression in 3T3-L1 and human adipocytes. Faseb J 15(1):215-220.
45. Sprecher H. 2000. Metabolism of highly unsaturated n-3 and n-6 fatty acids. Biochim Biophys Acta 1486(2-3):219-231.
46. Su CG, Wen X, Bailey ST, Jiang W, Rangwala SM, Keilbaugh SA, Flanigan A, Murthy S, Lazar MA, Wu GD. 1999. A novel therapy for colitis utilizing PPAR-gamma ligands to inhibit the epithelial inflammatory response. J Clin Invest 104(4):383-389.
47. Tontonoz P, Hu E, Graves RA, Budavari AI, Spiegelman BM. 1994. mPPAR gamma 2: Tissue-specific regulator of an adipocyte enhancer. Genes Dev 8(10):1224-1234.
48. Tontonoz P, Hu E, Devine J, Beale EG, Spiegelman BM. 1995. PPAR gamma 2 regulates adipose expression of the phosphoenolpyruvate carboxykinase gene. Mol Cell Biol 15(1):351-357.
49. Tontonoz P, Singer S, Forman BM, Sarraf P, Fletcher JA, Fletcher CD, Brun RP, Mueller E, Altiok S, Oppenheim H, Evans RM, Spiegelman BM. 1997. Terminal differentiation of human liposarcoma cells induced by ligands for peroxisome proliferator-activated receptor gamma and the retinoid X receptor. Proc Natl Acad Sci USA 94(1): 237-241.
50. Tzameli I, Pissios P, Schuetz EG, Moore DD. 2000. The xenobiotic compound 1,4-bis[2-(3,5-dichloropyridyloxy)]benzene is an agonist ligand for the nuclear receptor CAR. Mol Cell Biol 20(9):2951-2958.
51. Wood LG, Fitzgerald DA, Gibson PG, Cooper DM, Collins CE, Garg ML. 2001. Oxidative stress in cystic fibrosis: Dietary and metabolic factors. J Am Coll Nutr 20(Suppl 2):157-165.
52. Wood LG, Fitzgerald DA, Lee AK, Garg ML. 2003. Improved antioxidant and fatty acid status of patients with cystic fibrosis after antioxidant supplementation is linked to improved lung function. Am J Clin Nutr 77(1):150-159.
53. Yung B, Noormohamed FH, Kemp M, Hooper J, Lant AF, Hodson ME. 2002. Cystic fibrosis-related diabetes: The role of peripheral insulin resistance and beta-cell dysfunction. Diabet Med 19(3):221-226.
54. Zhu Y, Alvares K, Huang Q, Rao MS, Reddy JK. 1993. Cloning of a new member of the peroxisome proliferator-activated receptor gene family from mouse liver. J Biol Chem 268(36):26817-26820.